media – Page 544 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Tooth Sensor Measures Intake of Sugar, Salt, Alcohol

Having an accurate record of food and alcohol intake is important for managing a number of diseases including diabetes, various cardiovascular conditions, and alcoholism. Currently, not much practical technology is available to do this aside from smartphone apps, and apps tend to be tedious and require constant vigilance of making sure to input all the data.
- Source: Med Gadget
- 1,319
- March 23, 2018
diabetes digital health Researches
Ddu Priority Products Recruitment Activity Online

In collaboration with Google, Facebook, Yahoo and LinkedIn, Ddu recently launched their priority products rally to help users on the platform capture business opportunities, hosting an online medical device product fair to get mass exposure for users' quality products.
- Source: Ddu
- 1,653
- March 22, 2018
Ddu News medical device
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases.
- Source: finance.yahoo
- 475
- March 22, 2018
Market Views neurodegenerative preclinical
Artificial intelligence firm twoXAR raises $10M for partnering drive

Artificial intelligence company twoXAR—a specialist in separating signals from noise in data-rich drug discovery projects—has raised $10 million in a first-round financing led by SoftBank Ventures.
- Source: Fiercebiotech
- 574
- March 22, 2018
diabetes financing Market Views
Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. At this interim analysis a statistically significant overall survival (OS) benefit was not observed and the study will continue as planned. These data will be presented at an upcoming oncology congress.
- Source: cleveland19
- 736
- March 22, 2018
Chemotherapy Clinical Trials Genentech NSCLC oncology
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
- Source: finance.yahoo
- 588
- March 22, 2018
ADCETRIS cancer FDA Hodgkin lymphoma New Approvals
Oxford Performance Materials targets Asia after 3D printed medical devices approved in Japan

Oxford Performance Materials, a company whose materials have been used in everything from medical implants to Boeing airplanes, has been given the green light to distribute its 3D printed medical devices in Japan, paving the way for major expansion within Asia.
- Source: 3Ders
- 537
- March 22, 2018
3D printing Japan medical device products New Approvals
New wearable brain scanner allows patients to move freely for the first time

A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham and the Wellcome Centre for Human Neuroimaging, UCL. It is part of a five-year Wellcome funded project which has the potential to revolutionize the world of human brain imaging.
- Source: Medical Xpress
- 558
- March 22, 2018
brain medtech Researches
New AI technique dramatically improves the quality of medical imaging

AUTOMAP offers a number of potential benefits for clinical care, even beyond producing high-quality images in less time with MRI or with lower doses with X-ray, CT and PET. Because of its processing speed, the technique could help in making real-time decisions about imaging protocols while the patient is in the scanner.
- Source: Artificial Intelligence Research
- 481
- March 22, 2018
AI imaging machine learning Researches
4 Ways to Find Medical Device Buyers in 2018

Those who are engaged in foreign trade have undoubtedly realized that it is getting trickier to secure reliable customers even though they send thousands of development letters. So, with increasing competition, how is it possible to obtain more target clients? In the long run, improving product competitiveness and branding may look like the choice we will take, but what are the most efficient short term methods of customer development?
- Source: Ddu
- 1,186
- March 21, 2018
customer development Ddu College

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.